NOVEL POLYMORPHIC FORMS OF 6-(1-METHYL-1H-PYRAZOL-4-YL)-2-{ 3-[5-(2-MORPHOLIN-4-YL-ETHOXY)-PYRIMIDIN-2-YL]-BENZYL} -2H-PYRIDAZIN-3-ONE DIHYDROGENPHOSPHATE AND PROCESSES OF MANUFACTURING THEREOF
594172 Disclosed herein are crystalline 6-(1-methyl-1H-pyrazol-4-yl)-2-{ 3-[5-(2-morpholin-4-yl-ethyoxy)-pyrimidin-2-yl]-benzyl} -2H-pyradizin-3-one dihydrogenphophate solvates and anhydrates； the use thereof in the treatment of physiological and/or pathophysiological conditions affected by modulation of signal transduction kinases, such as tyrosine kinases or Met-kinase, including cancer； and processes for the preparation thereof comprising recrystallisation from a solvent or solvent mixture and aqueous phosphoric acid solution. Specifically wherein the compound is the crystalline anhydrate, hydrate or dihydrate characterised by XRD peaks disclosed in the specification.
